Nuvaring
Product Images NDC 76413-131

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Nuvaring (NDC 76413-131). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Central Texas Community Health Centers, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Nuvaring 01)

A horizontal bar chart showing the number of women with a blood clot out of 10,000 woman-years across four groups: Non-CHC User Non-Pregnant, CHC User, Pregnancy, and Postpartum (12 weeks only). Each bar is divided into a dark segment and a white segment, representing ranges of values for blood clot incidence, with the postpartum group having the highest range compared to other groups.*

FDA Label Image

Chemical Structure (Nuvaring 02)

Chemical structures of the active ingredients Etonogestrel (C22H28O2) and Ethinyl Estradiol (C20H24O2) shown side by side with labeled carbon and oxygen atoms and molecular formulas.*

FDA Label Image

Figure 2 (Nuvaring 03)

A line graph showing blood concentration levels of etonogestrel and ethinyl estradiol (EE) over 21 days following insertion of the NuvaRing contraceptive. The x-axis represents days after NuvaRing insertion, while the left y-axis indicates etonogestrel concentration in pg/mL and the right y-axis shows EE concentration in pg/mL. Etonogestrel levels rise sharply and stabilize, while EE levels remain consistently lower.*

FDA Label Image

Figure 3 (Nuvaring 04)

A diagram illustrating the relative effectiveness of various birth control methods based on pregnancies per 100 women per year. It ranks methods from fewer pregnancies (less than 1 per 100) with implants, injections, intrauterine devices, and sterilization, to more pregnancies (85 or more per 100) with no birth control. Other methods shown include birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, and withdrawal.*

FDA Label Image

Figure 4 (Nuvaring 05)

A horizontal bar chart showing the number of women with a blood clot out of 10,000 woman-years (WY) across four groups: Non-CHC users non-pregnant, CHC users, pregnant women, and postpartum women (12 weeks only). Each category displays a range for blood clot incidence, with postpartum women showing the highest range from 40 to 65 cases.*

FDA Label Image

Figure A, Figure B, Figure C (Nuvaring 06)

An instructional illustration showing three figures labeled A, B, and C, each depicting a different body position for inserting or removing NuvaRing. Figure A shows a woman lying on her back with knees bent; Figure B shows a woman squatting; and Figure C shows a woman standing with one foot elevated on a step or chair.*

FDA Label Image

Figure D, Figure E (Nuvaring 07)

Illustrations showing hand positioning for the NuvaRing vaginal contraceptive ring. Figure D depicts holding the ring between thumb and forefinger by its outer edge. Figure E shows the ring being squeezed lengthwise between thumb and forefinger to prepare for insertion.*

FDA Label Image

Figure F (Nuvaring 08)

Illustration showing the anatomical placement of the NuvaRing vaginal contraceptive device inside the female reproductive system, labeled near the vagina and uterus.*

FDA Label Image

Figure G (Nuvaring 09)

An anatomical diagram showing female reproductive organs in a sagittal view with a hand inserting a flexible, circular device, illustrating the placement of NuvaRing vaginal ring inside the vagina.*

FDA Label Image

Figure H (Nuvaring 10)

An anatomical illustration showing a cross-sectional view of the female pelvic region with placement of the NuvaRing vaginal ring inside the vaginal canal near the cervix.*

FDA Label Image

Figure I (Nuvaring 11)

A black and white anatomical illustration showing the female reproductive system in sagittal view, depicting the placement of a vaginal ring contraceptive device inside the vaginal canal near the cervix.*

FDA Label Image

Figure J (Nuvaring 12)

An instructional illustration labeled 'Figure J' shows the insertion of NuvaRing, a vaginal contraceptive ring, into the vaginal canal of a female figure using one hand. The diagram highlights the anatomical placement inside the vaginal area.*

FDA Label Image

Principle Display Panel (3 Pouch Box Label)

This image contains patient instructions for NuvaRing, a vaginal contraceptive ring. It directs to place a new NuvaRing every 4 weeks and remove it after the third week, presented in both English and Spanish. The label includes dispensing information such as batch, lot numbers, expiration date, and a legal transfer notice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.